Skip to Content
Merck
CN

F8257

Flunarizine dihydrochloride

≥98% (TLC), T-type Ca2+/Na+ channel blocker

Synonym(s):

1-[Bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine dihydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C26H26F2N2 · 2HCl
CAS Number:
30484-77-6
Molecular Weight:
477.42
NACRES:
NA.77
PubChem Substance ID:
24277835
UNSPSC Code:
12352200
EC Number:
250-216-6
MDL number:
MFCD00058198
Beilstein/REAXYS Number:
4284243

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Flunarizine dihydrochloride, ≥98% (TLC)

InChI key

RXKMOPXNWTYEHI-RDRKJGRWSA-N

InChI

1S/C26H26F2N2.2ClH/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21;;/h1-15,26H,16-20H2;2*1H/b7-4+;;

SMILES string

Cl[H].Cl[H].Fc1ccc(cc1)C(N2CCN(CC2)C\C=C\c3ccccc3)c4ccc(F)cc4

assay

≥98% (TLC)

originator

Johnson & Johnson

storage temp.

2-8°C

Quality Level

200

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Flunarizine dihydrochloride has been used to study the effect of flunarizine on epileptiform activity. It is also used to study its effect on high-potassium induced increase of intracellular free calcium.

Biochem/physiol Actions

Blocks T-type Ca2+/Na+ channels.
Blocks T-type Ca2+/Na+ channels; inhibits K+-induced catecholamine release from chromaffin cells

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Flunarizine has antihistamine, anticonvulsant and vestibular depressive properties. It protects endothelial cells from calcium overload-induced damage. Flunarizine is used to treat epilepsy, migraine prophylaxis, cerebral blood flow disturbances, peripheral vascular disease and vertigo.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000514925
0000514925
0000451097
0000451097
0000461962

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Flunarizine
Holmes B, et al.
Drugs, 27(1), 6-44 (1984)
The effect of flunarizine on penicillin model epilepsy in rats
BAGIRICI F, et al.
Journal of Experimental and Clinical Medicine, 16(4) (1999)
Effects of flunarizine on induced calcium transients as measured in fura-2-loaded neurons of the rat dorsal root ganglion
Leybaert L, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology, 348(3), 269-274 (1993)
Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy
Overweg J, et al.
Epilepsia, 25(2), 217-222 (1984)
R Aishworiya et al.
Annals of tropical paediatrics, 31(2), 149-152 (2011-05-18)
Alternating hemiplegia of childhood (AHC) is a rare neurological disorder which usually presents before 18 months of age and is characterised by recurrent alternating episodes of hemiparesis. A single effective treatment for this condition is yet to be established; flunarizine
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service